Introduction {#s1}
============

The Adenomatous Polyposis Coli (APC) gene, located on chromosome 5q21--q22, consists of 15 coding exons, which translate into a 2843 amino acid multifunctional protein. Its various motifs and domains allow binding to key players of the Wnt pathway and cytoskeleton components.[@R1] *APC* germline mutations cause autosomal dominant colon cancer predisposition, known as familial adenomatous polyposis (FAP), which is characterised by hundreds to thousands of colorectal adenomatous polyps. Three FAP clinical variants are correlated with the location of *APC* mutations, the large majority of which spans the 5′-half of the gene: (1) classic FAP with profuse polyposis (\>1000 adenomas), associated with mutations from codons 1250 to 1424; (2) attenuated FAP (AFAP, \<100 adenomas), associated with mutations at *APC* extremities (before codon 157 and after codon 1595); (3) classic FAP with intermediate colonic polyposis (100--1000 adenomas).[@R2]

A variable range of extracolonic manifestations, including desmoid tumours (DTs) and upper gastrointestinal (GI) polyps, have been associated with mutations in *APC* specific regions.[@R2] Specifically, DT occurrence in patients with FAP has been linked with mutations at codons 1445--1578[@R3] and, less frequently, beyond codon 1444.[@R4] Although still controversial, associations between upper GI polyposis phenotype and germline APC mutations have been described: gastric/duodenal adenomas have been associated with APC mutations at codons 564--1465[@R5] and codons 976--1067.[@R6] Moreover, germline mutations in *APC* promoter 1B have been identified in patients with hereditary gastric adenocarcinoma and proximal polyposis of the stomach,[@R7] which is characterised by a carpeting of more than 100 fundic gland polyps (FGPs). Overall, truncations at APC extreme C-terminal have been rarely reported and have not been clearly associated with a specific phenotype.

Here, we report that mutations affecting *APC* distal portion identify a novel FAP clinical phenotype, which we termed Gastric Polyposis and Desmoid FAP (GD-FAP).

Methods {#s2}
=======

Patients {#s2-1}
--------

We identified one family whose members share clinical findings of profuse gastric polyposis, restricted to the stomach body and fundus, while presenting few colon polyps along with DTs. All subjects included in this analysis provided written informed consent for genetic analysis. All investigations were performed in accordance with the World Medical Association's Declaration of Helsinki.

Mutation analysis {#s2-2}
-----------------

Genomic DNA was purified from peripheral blood lymphocytes according to manufacturer's instructions (QIAamp DNA Blood Mini Kit; Qiagen, Carlsbad, California, USA). The *APC* complete coding region was screened for mutations as previously described.[@R8] *APC* promoter 1B was analysed for mutations using a PCR~~-~~direct sequencing method as previously reported.[@R7] Sequencing and capillary electrophoresis were performed on the Applied Biosystems 3130 Genetic Analyzer (ThermoFisher Scientific, Waltham, Massachusetts, USA). Mutations and polymorphisms were conﬁrmed in independently ampliﬁed PCR products. *APC* deletions were identified by Multiplex Ligation-dependent Probe Amplification (MLPA) analysis, using the SALSA P043 Multiplex Ligation-dependent Probe Amplification (MLPA) kit (MRC-Holland, Amsterdam, The Netherlands) according to the manufacturer's instructions. MLPA products were run on the Applied Biosystems 3130 Genetic Analyzer. Results were then processed with the Coffalyser software (MRC-Holland). Probes with a dosage ratio \<0.7 or \>1.3 revealed deletions or duplications in the corresponding sequences, respectively.

Meta-analysis {#s2-3}
-------------

The meta-analysis was performed on the Human Gene Mutation Database Professional (HGMD Professional; Qiagen), a comprehensive collection of germline mutations in nuclear genes that are associated with human-inherited diseases.[@R9] The main β-catenin-downregulating APC domains are located before codon 2051. Therefore, we considered the region beyond codon 2051 and the region coding for the last β-catenin-regulating domain of *APC* (codons 2031--2051) to better define the phenotypes associated with germline truncating mutations at *APC* 3′-end. We reviewed all the papers identified in the aforementioned database and collected clinical information (i.e., gender, age of diagnosis, gastric or colon polyposis, DTs and specific *APC* mutations) concerning patients with truncating mutations at *APC* 3′-end. Studies including patients without clinical information were excluded.

Results {#s3}
=======

Family clinical findings {#s3-1}
------------------------

Here we report an Italian family in which a woman was diagnosed with rectal cancer (at the age of 64) and her three children developed multiple DTs and profuse gastric polyposis at an early age (second and third decade) in the absence or paucity of colonic polyposis ([figure 1A, B](#F1){ref-type="fig"}). The mother underwent surgical resection of rectal cancer and died one month later due to septic fever secondary to anastomotic dehiscence; thus, no upper gastrointestinal endoscopy (UGE) was performed. Preoperative colonoscopy did not reveal colon polyps. Affected family member II-1 was diagnosed with numerous small sessile polyps in the stomach fundus and body and two tubular adenomas of the colon at the age of 31. One year later, a small sessile polyp of the sigmoid colon was detected by colonoscopy and surgically removed. UGE revealed multiple gastric polyps in the fundus and body, two of which were histologically characterised as FGPs. Affected family member II-2 was diagnosed with a localised tumour composed of cells with tapering nuclei and extracellular collagen in the stroma (DT) by abdominal CT at the age of 24. Two years after surgical intervention, he developed four novel abdominal DTs, which were surgically resected. The patient underwent regular follow-up with annual colonoscopies, which showed no evidence of polyposis. At the age of 28, the patient was diagnosed with tumour recurrence by MRI and subsequently underwent combined chemotherapy (vinorelbine and methotrexate), which produced significant DT regression. At the age of 30, the patient was diagnosed with a squamous papilloma of the esophagus, which was surgically removed, and multiple gastric sessile polyps, some of which were histologically characterised as FGPs. At the age of 26, the affected family member II-3 underwent UGE, which showed multiple gastric polyps (0.2--0.8 cm) in the stomach fundus and body. After histological analysis, four gastric polyps were classified as FGPs ([figure 1C](#F1){ref-type="fig"}). Moreover, the patient developed several small duodenal polyps and duodenal adenomas with low grade of dysplasia. Between the age of 26 and 30, the patient was diagnosed with multiple DTs at different sites, including the hypogastric and epigastric region of the abdominal wall, the inguinal area and the pancreas.

![Family pedigree and relevant clinical findings in individual patients. (A) Squares indicate men, circles represent women. Unfilled symbols indicate unaffected individuals. A slashed symbol indicates that an individual is deceased. Black filled symbols represent individuals carrying the APC mutation. y indicates the age at latest follow-up. For patient I-2, the age at diagnosis (years) of colorectal cancer (CRC) is also indicated. (B) Relevant clinical findings in individual family members (II-1, II-2, II-3) are depicted as filled circles (red circles indicate gastric polyps (GPs); green circles indicate colon polyps (CPs); blue circles indicate desmoid tumours (DTs)); y represents the age at diagnosis of the reported clinical observations. The number of GPs and CPs is indicated. Predominant siding of DTs is also indicated and mapped according to age at diagnosis (years): Abs, abdominal rectal muscle; AbW, abdominal wall; Ing. Area, inguinal area. (C) Endoscopic view showing GPs of affected family member II-3.](jmedgenet-2019-106299f01){#F1}

Characterisation of APC germline mutation {#s3-2}
-----------------------------------------

The *APC* mutation search performed on the index case's DNA revealed a nonsense mutation in *APC* exon 15 (NM_000038.5:c.7709C\>G; p.Ser2570Stop). The proband's mutation was inherited from the mother and was also present in one brother and one sister ([figure 1A](#F1){ref-type="fig"}). Sequencing of *APC* promoter 1B excluded the presence of three mutations (chr5:112,707,523 A/C; c.-195A\>C; and chr5:112,707,527 T/C; c.-191T\>C; chr5:112,707,593 A/\_; c.-125delA) --- previously identified in patients with hereditary gastric adenocarcinoma and proximal polyposis of the stomach [@R7] --- in the DNA of all analysed family members but revealed a single nucleotide variant (chr5:112,707,473 A/C; c.-245A/C; rs75580617) in the DNA of family member I-2. Analysis using the 1000 Genomes database (<http://www.internationalgenome.org>) revealed that the rs75580617 variant had a minor allele frequency \>5%, indicating that it could be considered a common variant. MLPA analysis excluded deletions and duplications involving *APC* in all family members.

Meta-analysis results {#s3-3}
---------------------

Our meta-analysis, aimed at identifying clinical phenotypes specifically associated with germline truncating mutations in APC extreme 3′-end, revealed that a very small proportion (n=21/1418, 1.5%) of APC truncating mutations disrupts the protein C-terminal region. This region, starting at amino acid (aa) 2052, does not include motifs and domains involved in β-catenin downregulation, while it encompasses the basic domain (aa 2224--2575) and binding sites for both EB1 (aa 2670--2843) and DLG (aa 2841--2843) proteins. The remaining 1397 truncating mutations represent the majority (72%) of total *APC* germline alteration burden (n=1951) and cluster 5′ to codon 2052, leading to partial or total removal of domains involved in β-catenin regulation ([figure 2A](#F2){ref-type="fig"}). Thus, we sought to compare the phenotypic consequences of truncating mutations falling within the third SAMP repeat --- APC last β-catenin-regulating domain (region A: aa 2031--2051) --- to those harboured in APC extreme C-terminal region, distal to SAMP3, which does not contain β-catenin-regulating domains (region B: aa 2052--2843). A total of 35 unique alterations localising to these two different APC distal regions were recorded: (1) 14 were located in the third SAMP repeat domain, which is implicated in Axin binding (APC region A),[@R10] and (2) 21 created a stop codon in the distal part of the protein, which includes the binding domains for EB1 and DLG (APC region B).[@R11] Among this subset of 35 terminating mutations, only 14 were identified in patients (n=101) with data on clinical features (polyps, tumours, desmoids); of these, 6 (77 patients) were located in APC region A and 8 (24 patients) in APC region B, which also harbours the mutation characterised in the present study ([figure 2B](#F2){ref-type="fig"}). The clinical features of these patients and of the family we identified are detailed in [online supplementary table 1](#SP1){ref-type="supplementary-material"}. In this cohort, the percentage of patients with a lower count of colon polyps (\<50) was significantly higher among patients with mutations in APC region B (p=0.0151). Moreover, the frequency of profuse gastric polyposis or adenomas was higher in patients with APC truncated in region B than in region A (p=0.0461). Finally, DTs were over-represented in patients with truncating mutations in APC region B (77.8%) compared to patients harbouring mutations in APC region A (25%) ([table 1](#T1){ref-type="table"}).
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###### 

Relevant clinical features of patients harbouring truncating variants in APC region A and APC region B

  -----------------------------------------------------------------------
  Phenotype   APC region A\   APC region B\   Fisher exact test p-value
              N (%)           N (%)           
  ----------- --------------- --------------- ---------------------------
  CP \>50     47/66 (71.2)    3/22 (13.6)     0.0151

  CP \<50     19/66 (28.8)    19/22 (86.4)    

  GPP/Ad+     15/62 (24.2)    7/13 (53.84)    0.0461

  GPP/Ad−     47/62 (75.8)    6/13 (46.15)    

  DT+         19/76 (25)      14/18 (77.8)    \<0.0001

  DT−         57/76 (75)      4/18 (22.2)     
  -----------------------------------------------------------------------

CP, colon polyp; DT, desmoid tumour; GPP/Ad, gastric profuse polyposis/adenoma.

![*APC* coding region and genotype--phenotype correlation (A) Distribution of truncating mutations throughout *APC* coding region and genotype--phenotype correlation. Conserved regions and domains that interact with other proteins are shown. (B) Distribution of mutations in the extreme 3′-end of *APC* coding region in patients with clinical information identified in our literature meta-analysis and in the present study. Light blue and yellow boxes with arrows indicate the location of premature stop codons of already described truncating mutations in APC regions A and B, respectively. The nonsense mutation identified in our patients, which causes a stop at codon 2570, is indicated with a yellow arrow and circle.](jmedgenet-2019-106299f02){#F2}

Discussion {#s4}
==========

The location of *APC* mutations influences FAP phenotype and surveillance/treatment.[@R1] To date, over 1900 *APC* mutations have been described in FAP; of these, more than 70% occur 5′ to codon 1600, thus leading to the loss of β-catenin-regulating APC domains. Mutations truncating APC C-terminus cause the loss of domains required for microtubule binding and EB1/DLG interaction, potentially triggering loss of polarisation, inhibition of differentiation and chromosomal instability.[@R11] *APC* mutations in this specific region are extremely rare and have not been obviously associated with a distinct phenotype. In this study, we sought to elucidate the correlation between mutations located at *APC* extreme 3′-end and clinical symptoms. Our results demonstrate a trend towards a lower susceptibility to developing severe colonic polyposis (\>50) in patients with mutations in APC region B (aa 2052--2843) compared to patients with mutations in APC region A (aa 2031--2051). Where mutations do not affect the Axin binding site (SAMP3 domain) in APC, its β-catenin-degrading activity is preserved, which may explain the association with the oligo-polyposis phenotype. It is also noteworthy that patients with mutations in APC region B appear to have a higher risk of developing DTs and a higher susceptibility to developing profuse gastric polyposis or adenomas. Thus, it is tempting to speculate that truncating mutations in APC region A trigger Wnt-dependent oncogenic proliferation, which may drive substantial catastrophic consequences on a constantly renewing tissue such as the colon epithelium (short lifespan: 3--5 days).[@R14] Conversely, truncating mutations in APC region B likely cause the loss of cell/tissue polarisation, which is a tumour suppressor mechanism. This could subvert the architectural structure of the gastric tissue, in which parietal cells have an extended lifespan of 54 days, and/or lead to deregulation of mesenchymal proliferation.[@R15] Importantly, gastric adenomas in the gastric body/fundus may arise in a background of numerous (carpet-like) FGPs. Consistently, previous studies have shown adenomatous dysplastic changes within FGPs in about 40% of FAP patients with FGPs.[@R16] In our study, among 13 clinically characterised patients with truncating mutations in APC region B, five out of seven have developed adenomas in association with FGPs. These findings may have important consequences on surveillance, tailored management and overall quality of life of FAP patients. We are aware that our study has some limitations, the major one being the number of patients without available clinical information. Also, it must be noted that DTs can remain undetected on conventional radiograph,[@R17] thus we cannot exclude the presence of these tumours in patients for which no data were reported about specific investigations. In conclusion, we report novel insights on FAP presentation when it is associated with mutations lying in APC extreme C-terminal region, supporting an emerging FAP clinical phenotype, which we termed Gastric Polyposis and Desmoid FAP (GD-FAP). Based on the National Comprehensive Cancer Network guidelines[@R18] for AFAP patients and on the higher risk of developing adenomas that has been observed in FAP patients with FGPs,[@R19] in our view, GD-FAP patients should start follow-up at the age of 20 by performing colonoscopy every 2--3 years, esophagogastroduodenoscopy and abdominal ultrasound annually.
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